By Ed SilvermanAug. 11, 2026
Pharmalot Columnist, Senior Writer
Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again. And to celebrate, we are brewing still more cups of stimulation and inviting you to join us. Our choice today is blackberry hibiscus. Remember, a prescription is not required. So no need to mess with rebates or even TrumpRx. Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch. …
The U.S. Food and Drug Administration rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis, STAT notes. The drug had been developed by ITM Isotope Technologies Munich SE, a long-standing player in the field of radiopharmaceuticals, which are an emerging treatment designed to shoot radioactive isotopes directly at tumor cells. The company had been anticipating the FDA would sign off on the drug and last month launched a new division, Lumara Bio, to commercialize and sell it.
Hims & Hers plans to jump into the peptides market before the end of the year, seeing opportunity to seize on a booming corner of the health industry, Bloomberg News says. The telehealth company is preparing to sell already-allowed popular compounds that patients seek for wellness and longevity benefits despite limited clinical evidence. The plan comes as the FDA decides whether to loosen restrictions on seven different compounds. Last month, the agency held a hearing in which outside advisers recommended easing limits on production and expanding access.
